MarketLine Blog

Posts about Pharmaceuticals

Global generics market to experience double-digit growth through to 2021, says MarketLine

MarketLine

The global generics market has experienced dynamic growth in recent years, registering a compound annual growth rate (CAGR) of 11.1% between 2012 and 2016 to reach a value of $318 billion, according to data from research company MarketLine. The company’s latest report states that Asia-Pacific was comfortably the largest region in value terms, accounting for over 46% of the global total in 2016. The US followed with over 31%, while Europe continued to lag behind, contributing only 15.6%. The US once again reigned supreme as the single biggest country market,… Read more

Sequencing Quinoa: Food for thought

MarketLine

The pharmaceutical industry has been growing at a strong rate in recent years. One aspect of this market is that of the food supplement. The growing trend especially amongst the older populace and with the hectic lifestyles that are led in developed countries lends support to the supplement industry. The ability of scientists to understand the functions of different genes have assisted in the growth of specific markets and also in the changes to specific plant species. When looking at some of the historic plant species and how they have… Read more

Nude Makeup: Makeup is the new natural look

MarketLine

Historically, makeup was seen as a thing only used by grownups, however makeup being used by younger demographics is a growing trend. Trends now focus on teaching younger individuals how to use makeup with a recent quote suggesting that ‘nude makeup is the new natural’. Children are now being brought up to believe that makeup is natural and needed in order for them to look good. TV shows such as Toddlers and Tiaras further glamorize the use of makeup on children. Younger individuals using makeup has stimulated the appearance of… Read more

Brexit and Trump’s disastrous effect on science

MarketLine

2016 has been a rollercoaster of a year with regards to political incidences. With the UK voting in favor of leaving the EU in June 2016 and then a follow up of the US voting for President-elect Donald Trump in November of the same year, this has led to a degree of uncertainty in the scientific field. With funding at the forefront of scientific research and the advancement of scientific breakthroughs, the future has been thrown into turmoil as the individuals working in both countries, the US and the UK,… Read more

Generic drugs prices: Unscrupulous companies increase prices significantly

MarketLine

Generic drugs are identical in dose, strength, safety, efficacy, administration and intended use to their branded counterparts. They are produced after a product’s patent has expired, after 20 years. They are much cheaper to produce and these savings are passed on to the buyer: generics are much cheaper than their branded counterparts. An investigation by UK newspaper The Times, the findings of which were released in a June 2016 report, found that a small number of UK companies have made huge profits after increasing the prices of generic drugs. The… Read more

Pfizer and AstraZeneca: merger of majors cancelled or just postponed?

MarketLine

Pfizer is currently the world’s largest research-based pharmaceutical company, with 2013 revenues (excluding consumer health) of $47.9 billion. Recently, it made a bid for the UK’s AstraZeneca (2013 revenues of $25.7 billion) equivalent to £50 ($78) per share. This valued the company at more than £63 billion ($98 billion). A lot of money, you might think, but AstraZeneca lost no time in rejecting the offer. The same thing happened back in January this year, when the American company valued AstraZeneca at around £59 billion. Its CEO commented of the latest… Read more

2014: a year of transition at Teva

MarketLine

Teva Pharmaceuticals is a global leader in the pharmaceuticals industry, providing medicines to people all over the world. Teva is a giant in generic medicine and is the number one global producer of generic drugs worldwide. In Teva’s 2013 Annual Report, it stated that it was one of the top 10 pharmaceuticals companies in the world. One of Teva’s best-selling products, and the source of much of their transition, Copaxone, is used for relapse-remitting multiple sclerosis, an autoimmune disease which affects the central nervous system, damaging the nerves of the… Read more

Will biosimilar drug Inflectra be Remicade’s nemesis?

MarketLine

On 10 September 2013, Hospira announced that the European Commission had approved its drug Inflectra, a treatment for severe inflammatory conditions such as Crohn’s disease and rheumatoid arthritis. Good news for the company, and of course for patients suffering from these painful and debilitating diseases. Celebrations might be more muted at the headquarters of Johnson & Johnson, however, as Inflectra is essentially a legal copy of its blockbuster drug Remicade. Genuine generic copies of biotech drugs are not feasible, because competitors to the original manufacturer do not have access to… Read more

Pfizer re-entring to the OTC healthcare market

MarketLine

Pfizer Inc., the world’s largest pharmaceutical company, exited the over-the-counter (OTC) healthcare market in 2006 with the sale of its Consumer Healthcare division to Johnson & Johnson. Just 3 years later, in 2009, Pfizer re-entered the market with its acquisition of Wyeth. This article will examine the rise of Pfizer into a diversified healthcare company, the circumstances that led to the disposal of the Consumer Healthcare division, and the subsequent re-entry to the OTC market in 2009. Pfizer, Inc. was originally founded as fine chemicals business. Following a series of… Read more

Remicade, a Biotech Blockbuster in Treating a Variety of Immune System Diseases

MarketLine

Remicade is a drug used in treating a variety of immune system diseases, and its active ingredient is produced through biotechnology.  Johnson & Johnson reported Remicade sales of $4.6 bn in 2010, and the drug is the best-selling “biologic” in the world. This article examines its long journey from an academic research laboratory to a leading position in the pharmaceutical market. In 2010, the world’s best-selling biologic drug was Remicade. Since its original US Food and Drug Administration (FDA) approval as a treatment for Crohn’s disease in 1998, global sales… Read more

Dexcom Case Study: Launching a Continuous Glucose Monitor

MarketLine

Continuous glucose monitors (CGMs) promise certain diabetics more effective self-management of their condition. Medtronic is a leading US supplier of CGMs, but since 2006 it has faced competition from a small start-up, Dexcom. Management of diabetes often requires electronic blood glucose testing. Until recently, this was done using meters that offered single measurements. Continuous monitors came on to the US market in 2001 and offer certain diabetics the prospect of improved management of their condition, by detecting abnormal glucose levels more rapidly. Medtronic and Dexcom are the only players in… Read more